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Abstract
Integrity of the thymus during perinatal life is necessary for a proper maturation of the pituitary-
gonadal axis in mice and other mammalian species. Thus congenitally athymic (nude) female mice
show significantly reduced levels of circulating gonadotropins, a fact that seems to be causally related
to a number of reproductive derangements described in these mutants. Interestingly, a number of in
vitro studies suggest that the thymic peptide thymulin may be involved in thymus-pituitary
communication. To determine the consequences of low serum thymulin in otherwise normal animals,
we induced short (8 days)- and long (33 days)-term thymulin deficiency in C57BL/6 mice by
neonatally injecting (intraperitoneally) an anti-thymulin serum and assessed their circulating
gonadotropin levels at puberty and thereafter. Control mice received an irrelevant antiserum.
Gonadotropins were measured by radioimmunoassay and thymulin by bioassay. Both long- and
short-term serum thymulin immunoneutralization resulted in a significant reduction in the serum
levels of gonadotropins at 33 and 45 days of age. Subsequently, we injected (intramuscularly) an
adenoviral vector harboring a synthetic DNA sequence (5′-
ATGCAAGCCAAATCTCAAGGTGGATCCAACTAGTAG-3′) encoding a biologically active
analog of thymulin, methionine-FTS, in newborn nude mice (which are thymulin deficient) and
measured circulating gonadotropin levels when the animals reached 52 days of age. It was observed
that neonatal thymulin gene therapy in the athymic mice restored their serum thymulin levels and
prevented the reduction in circulating gonadotropin levels that typically emerges in these mutants
after puberty. Our results indicate that thymulin plays a relevant physiological role in the thymus-
pituitary-gonadal axis.
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DURING PERINATAL LIFE, the integrity of the thymus is necessary for a proper maturation of the pituitary-
gonadal axis as revealed by the endocrine alterations caused by neonatal thymectomy or
congenital absence of the thymus in mice. In effect, congenitally athymic (nude) female mice
show significantly reduced levels of circulating gonadotropins, a fact that seems to be causally
related to a number of reproductive derangements described in these mutants (24). Thus, in
homozygous (nu/nu) females, the times of vaginal opening and first ovulation are delayed
(2), fertility is reduced (24), and follicular atresia is increased such that premature ovarian
failure results (19). Similar abnormalities result from neonatal thymectomy in normal female
mice (20,22). In homozygous adult nude CD-1 male mice, gonadotropin responses to
immobilization stress are reduced as also are serum basal levels of the same hormones
compared with the heterozygous counterparts (14).
Thymulin is a well-characterized thymic factor discovered, purified, and sequenced during the
1970s (1). It consists of a biologically inactive nonapeptide component, FTS (an acronym for
serum thymus factor in French), coupled in an equimolecular ratio to the ion zinc (12), which
confers biological activity to the molecule (10). The metallopeptide active form bears a specific
molecular conformation that has been evidenced by nuclear magnetic resonance (7). There is
documented evidence that thymulin possesses gonadotropin-releasing activity. Thus thymulin
has been shown to stimulate luteinizing hormone (LH) release from perifused rat pituitaries
(29). Thymulin stimulated gonadotropin release from dispersed rat pituitary cells in a dose-
related manner, an effect that declined with the age of the pituitary cell donors (5).
In the present study we report that experimental induction of thymulin deficiency in normal
mice mimics the alterations in serum gonadotropins documented in neonatally thymectomized
and nude mice. Furthermore, using a recombinant adenoviral (RAd) vector, RAd-metFTS,
which harbors a synthetic DNA sequence encoding a biologically active analog of thymulin,
methionine-FTS (metFTS), we have been able to demonstrate that neonatal thymulin gene
therapy in nude mice completely prevents the reduction in circulating gonadotropin levels that
typically emerges in these mutants after puberty.
MATERIALS AND METHODS
Immunoreagents and FTS Synthesis
Anti-FTS was raised by immunizing rabbits with synthetic FTS coupled to keyhole limpet
hemocyanin (KLH; Sigma Aldrich, St. Louis, MO) as carrier. Anti-KLH, used as an irrelevant
antiserum, was raised by immunizing rabbits with KLH alone. In some experiments, normal
rabbit serum (NRS) was used as control serum instead of anti-KLH.
Antisera were initially tested and selected by dot blot with synthetic thymulin or KLH as
antigens. A nonapeptide possessing the amino acid sequence of native FTS (PyrGlu-
AKSQGGSN) was synthesized, employing an ABI 433A automated peptide synthesizer
(Applied Biosystems, Darmstadt, Germany), using the Fmoc/tBu strategy. The crude peptide
was purified by reverse-phase HPLC under standard conditions, with spectrophotometric
monitoring at λ = 220 nm, which led to obtaining a single peak of pure peptide.
Animals and Experimental Procedures
Immunoneutralization experiments—Pregnant C57BL/6 female mice were purchased
from Janvier (Le Genest, Saint-Isle, France) and kept in the animal facilities of Hôpital Necker,
Paris. The offspring of these mice were submitted to the quenching experiments described
below. Animals had free access to food and water and were kept at 22°C with a 12:12-h light-
dark cycle. Animal experiments with C57BL/6 mice were conducted in conformity with the
rules established by the European Union ethics committee for animal research.
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Gene therapy experiments—The offspring of NIH homozygous (nu/nu) nude male and
heterozygous (nu/+) female mice were used. The parent mice were purchased from the Animal
Core Facility of the National University of La Plata (ACFNULP), Argentina. All mice were
maintained on a γ-irradiate chow diet and sterilized water. Animals had free access to food and
water and were kept at 22°C with a 12:12-h light-dark cycle. All experiments on nude animals
were done following the Animal Welfare Guidelines of the National Institutes of Health
(Instituto de Investigaciones Bioquimicas de La Plata's Animal Welfare Assurance No.
A5647-01).
Prepubertal nu/nu mutants from ACFNULP have minimal levels of circulating thymulin.
During a short time window after puberty, they display a slight increase in serum thymulin
levels, which fall to nondetectable levels at around 3 mo of age, remaining so afterward. At
postnatal day 1 or 2, each experimental pup (both nu/nu and nu/+) received a single bilateral
intramuscular (hindlimb) injection of 108 plaque forming units of RAd-metFTS or RAd-GFP/
TK (a control vector; see Adenoviral Vectors Used) in 10 μl of vehicle (5 μl per side). On
postnatal days 51 and 52, mice were bled and immediately killed by cervical dislocation. On
postnatal day 13, three mice from each group were also bled for thymulin determination.
Injections of Antisera and Thymulin
Antiserum injections—On postnatal days 1 and 2, each C57BL/6 pup received an
intraperitoneal injection of 20 μl of the corresponding undiluted serum. In the long-term
quenching experiments, the initial two intraperitoneal antiserum injections were followed by
intraperitoneal antiserum injections every 7 days at a dose of 8 μl serum/g body wt.
Synthetic FTS injections—At the indicated times, C57BL/6 pups received an
intraperitoneal injection of 60 pg of thymulin/g body wt. FTS-Zn was prepared 30 min before
injection by mixing equimolecular (10 nM) volumes of synthetic FTS and ZnCl2, both prepared
in phosphate-buffered saline (PBS).
Adenoviral Vectors Used
RAd-metFTS—A DNA sequence coding for the biologically active thymulin analog metFTS,
referred to as a synthetic gene for thymulin, was constructed (Fig. 1, A and B). A recombinant
adenoviral vector harboring the synthetic gene for thymulin was constructed by a variant of
the two-plasmid method (16), employing the AdMax plasmid kit (Microbix, Toronto, ON,
Canada). This kit uses a shuttle plasmid (pDC515) containing a multiple cloning site (MCS)
and an FLP recognition target (FRT) site for the yeast FLP recombinase. This cassette is flanked
by sequences of the adenovirus type 5 (Ad5) E1 region. The second plasmid of the kit, the
genomic plasmid pBHGfrt(del)E1,3 FLP, consists of the entire genome of Ad5, containing
deletions in the regions E1 and E3. Upstream of the E1 deletion, pBHGfrt(del)E1,3 FLP
contains an expression cassette for the gene of yeast FLP recombinase, and immediately
downstream of the E1 deletion, an FRT site has been inserted. Once the thymulin synthetic
gene was inserted into the shuttle, both plasmids were cotransfected into HEK-293 cells. In
cotransfected HEK-293 cells, FLP recombinase is readily expressed and efficiently catalyzes
the site-directed recombination of the expression cassette of pDC515-metFTS into the left end
of pBHGfrt(del)E1,3 FLP, thus generating the genome of the desired recombinant adenoviral
vector, RAdmetFTS (Fig. 1C). The newly generated RAd was rescued from HEK-293 cell
lysates and plaque purified. It was further purified by ultracentrifugation in CsCl gradient and
titrated by a serial dilution plaque assay.
RAd-(GFP/TK)fus—An adenoviral vector termed RAd-(GFP/TK)fus was constructed in our
laboratory following the general procedures outlined above and was used as a control vector
in the gene therapy studies. The vector harbors a hybrid gene encoding the Aequorea
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victoria enhanced green fluorescent protein fused to herpes simplex virus type 1 thymidine
kinase (GFP/TK)fus (a kind gift from Dr. Jacques Galipeau, McGill University, Montreal,
Canada). This hybrid gene is driven by the mouse cytomegalovirus promoter. The vector was
expanded in HEK-293 cells and was purified and titrated as indicated above.
Thymulin Bioassay
Biologically active thymulin was measured in serum by a rosette bioassay described in detail
elsewhere (8). This method is based on the ability of thymulin to restore the inhibitory effect
of azathioprine on rosette formation in spleen cells from thymectomized mice. The inhibitory
activity of samples was compared with that of a standard curve using synthetic thymulin. Serum
values were expressed as femtograms per milliliter of bioactive thymulin. This bioassay has
been previously validated against an ELISA for thymulin (25).
Pituitary Hormone Assays and Immunohistochemistry
Serum levels of LH and follicle-stimulating hormone (FSH) were measured by
radioimmunoassay using the mouse materials provided by Dr. A. F. Parlow, Pituitary
Hormones and Antisera Center, University of California, Los Angeles Medical Center. Serum
concentrations of LH and FSH were expressed in terms of mouse LH RP-2 and rat FSH RP-2,
respectively.
Pituitary sections (4 μm) were incubated for 1 h at room temperature with primary antibodies
against LH or FSH (murine; Dako, Carpinteria, CA) diluted 1:100. Thoroughly washed
sections were then treated for 30 min with a ready-to-use EnVision reaction system (Dako)
using the peroxide-sensitive chromogen diaminobenzidine for color development.
Statistical Analysis
Data are expressed as means ± SE unless otherwise indicated. Statistical comparisons among
experimental groups were performed using Student's t-test or ANOVA followed by Tukey's
test when the ANOVA was significant.
RESULTS
In Vitro and In Vivo Immunoneutralization of Thymulin
The anti-FTS serum used was highly effective in quenching the biological activity of thymulin
in vitro. The specificity of this immunoneutralizing activity was demonstrated by the fact that
neither anti-KLH serum nor NRS displayed any significant immunoneutralizing activity on
thymulin (data not shown).
A single intraperitoneal injection of anti-FTS serum (8 μl/g body wt) markedly reduced the
serum activity of endogenous thymulin in C57BL/6 infantile mice. This inhibition lasted for
at least 10 days (Fig. 2, inset).
Long-term thymulin immunoneutralization experiments—Long-term quenching of
serum thymulin (antiserum injections done every 7 days) from postnatal days1 and 2 to
postnatal day 33 induced a significant fall in the serum levels of LH and FSH in both male and
female C57BL/6 mice (Fig. 2).
Short-term immunoneutralization experiments—Serum thymulin was
immunoneutralized during a short postnatal time window as follows: pups were
intraperitoneally injected with an anti-FTS or anti-KLH serum on postnatal days 1 and 2. On
postnatal day 8, three animals from each experimental group were bled to confirm that serum
thymulin quenching had been successful; immediately afterward, all animals received an
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intraperitoneal injection of synthetic thymulin. On day 9, all pups received a second injection
of thymulin, and 2.5 h later, three animals from each group were bled to determine serum
thymulin levels. As expected, anti-FTS serum, but not control serum, induced a strong
reduction in circulating thymulin. The injection of synthetic thymulin saturated the anti-FTS
serum and returned serum thymulin to control values until postnatal day 45, when mice were
killed (Fig. 3).
Thymulin immunoneutralization during an 8-day neonatal window was still effective in
causing low serum LH and FSH levels when the mice achieved 45 days of age (Fig. 4). At the
end of both short- and long-term quenching experiments, the pituitaries of anti-FTS-treated
animals showed a mild decrease in the number of LH and FSH cells as well as a slight
hypertrophy of the same cells (Fig. 5).
Restorative Effect of RAd-metFTS Administration on Serum Thymulin in Nude Mice
A single neonatal intramuscular injection of RAd-metFTS, but not RAd-GFP/TK (a control
vector), increased the circulating levels of biologically active thymulin in both heterozygous
and homozygous nude mice tested at 51-52 days of age (Fig. 6). At 13 days of age, the RAd-
metFTS-treated nu/nu mice achieved serum thymulin levels comparable to those of control
nu/+ counterparts. At the same time point, RAd-metFTS-treated heterozygous mice showed a
clear increase in the serum levels of thymulin compared with control counterparts (Fig. 6).
Neonatal Thymulin Gene Therapy Prevents Serum LH and FSH Deficits in Adult Nudes
A single neonatal intramuscular injection of RAd-metFTS, but not RAd-GFP/TK, prevented
the development of hypogonadotropinemia in postpubertal nudes and induced
supraphysiological serum levels of LH and FSH in the heterozygous mice (in nu/+ mice, this
increase only achieved statistical significance for LH; Fig. 7).
DISCUSSION
Thymulin is a thymic metallopeptide involved in several aspects of intra- and extrathymic T-
cell differentiation (1). Circulating levels of this molecule fall sharply in humans affected by
pathologies such as acquired immunodeficiency syndrome (17) and DiGeorge syndrome, a
syndrome characterized by the congenital absence of the thymus and parathyroid glands (18),
as well as during normal aging (6). Thymulin, which is exclusively produced by the thymic
epithelial cells (9), exerts a controlling feedback effect on its own secretion (28). In addition,
thymulin production and secretion are stimulated directly by growth hormone and prolactin
and indirectly by thyrotropin through thyroid hormones. Corticotropin and gonadotropins
inhibit thymulin secretion via a direct action of adrenal and gonadal steroids, respectively, on
thymic epithelial cells (13). Considering the multihormone control effected by the pituitary
gland on thymulin secretion, it seems logical to hypothesize that thymulin may in turn exert
feedback actions on the hypophysis and the hypothalamus.
To our knowledge, this is the first report documenting that immunoneutralization of a
circulating molecule specifically produced by the thymus can reproduce the gonadotropin
deficiencies caused by neonatal thymectomy or congenital absence of the thymus in mice.
Consequently, the present findings strongly point to thymulin as the physiological mediator,
or at least one of the mediators, of the perinatal influence of the thymus on the maturation of
the pituitary-gonadal axis. This is in line with studies showing that injection of synthetic
thymulin in the hypothalamus of prepubertal female mice has a facilitatory action on equine
chorionic gonadotropin-induced ovulation (11). The present results also indicate that thymulin
deficiency during the first 8 days of life is enough to induce low serum levels of gonadotropins
as well as morphological changes at pituitary level in the adult animals.
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We can only speculate on the physiological mechanism by which thymulin exerts its influence
on gonadotropic hormone secretion. Thymulin is known to possess hypophysiotropic activity
in vitro (3-5,15,29) and therefore may act directly on the adenohypophysis in vivo, modulating
the response of the gland to hypothalamic or other secretagogues or inhibitors. There also is
evidence that thymulin stimulates cytokine release from certain types of lymphocytes (23).
Therefore, thymulin could also influence gonadotropin production by stimulating the release
of cytokines or other neuroactive molecules from thymulin-responsive immune cells.
Since the gene for native FTS has not been cloned, we constructed an artificial DNA sequence,
optimized for expression in rat systems, which codes for a biologically active analog of FTS,
metFTS (25). This sequence was used to construct RAd-metFTS, an adenoviral vector able to
achieve long-term restoration of circulating thymulin levels when intramuscularly injected in
thymectomized rats and mice (25). Adenovirally delivered metFTS in the brain of
immunocompetent rats showed a much longer expression than adenovirally delivered GFP and
β-galactosidase (21). The ability of RAd-metFTS to achieve long-term expression in vivo was
also observed in the present study, where a single intramuscular injection of the vector resulted
in sustained expression of the transgene 51 days after the treatment despite the severalfold
increase in the size (and volemia) of the animals from the beginning to the end of the study.
Since thymulin and certain thymulin analogs have been reported to possess anti-inflammatory
activity in the brain (26,27), we hypothesize that an anti-inflammatory activity of thymulin
may have protected the adenovirally transduced cells from being destroyed by the immune
system of the host animals.
The finding that neonatal thymulin gene therapy prevents the well-documented deficit of
circulating gonadotropins in adult nudes complements our thymulin immunoneutralization
results in normal mice and lends further support to the view that thymulin is an important player
in the thymus-gonadotropic axis. In addition, our data suggest that thymulin gene therapy may
be an effective strategy to approach reproductive deficits associated with thymus dysfunction.
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DNA constructs encoding the thymulin analog methionine-FTS (metFTS) and a recombinant
adenoviral (RAd) vector for metFTS (RAd-metFTS). A DNA sequence coding for native serum
thymus factor (FTS) was designed for optimal expression in rat cells. By adding an ATG
starting codon upstream and 2 stop codons downstream of this sequence, we converted it into
an open reading frame (ORF) for the analog metFTS (A). This metFTS ORF was used to
generate a construct to be cloned in the shuttle vector pDC515. The construct included the
phage T7 promoter primer binding site, which was used for sequencing purposes (B). The
shuttle pDC515-metFTS was generated by inserting the T7-metFTS sequence into the BamHI-
SalI sites of the multiple cloning site of the shuttle pDC515. This construct was used to generate
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RAd-metFTS (C). For further details, see MATERIALS AND METHODS and Ref. 25. PmCMV, mouse
cytomegalovirus promoter; frt, recognition element for the yeast FLP recombinase; ITR,
inverted terminal repeats; ΔE1 and ΔE3, deletions in the Ad5 genome; SV40, simian virus 40
polyadenylation signal; Ψ, packaging signal.
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Effect of long-term thymulin quenching on gonadotropin serum levels in mice. Experimental
animals (shaded bars) received weekly intraperitoneal injections of rabbit anti-FTS serum
beginning at birth. Control mice (solid bars) received normal rabbit serum. LH, luteinizing
hormone; FSH, follicle-stimulating hormone. All mice were killed at 33 days postinjection.
Numbers over bars represent the number of mice assessed for the corresponding data point.
Inset: in vivo immunoneutralization of serum thymulin in mice. Effects of a single
intraperitoneal injection of undiluted rabbit anti-FTS serum (8 μl/g body wt) on thymulin serum
level in 15-day-old mice were determined. Error bars represent SE. *P < 0.05; **P < 0.01,
significance of differences between control and experimental mice.
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Short-term immunoneutralization of serum thymulin in mice. Experimental animals (shaded
bars) were intraperitoneally injected at postnatal days 1 and 2 with rabbit anti-FTS serum,
which was followed by 2 intraperitoneal injections of synthetic thymulin (FTS-Zn; 60 pg/g
body wt) on postnatal days 8 and 9. Control mice (solid bars) were submitted to the same
treatment except that they received a rabbit anti-keyhole limpet hemocyanin (KLH) serum
instead of anti-FTS. Asterisks represent significance of differences between control an
experimental mice at each time point.
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Effect of short-term thymulin quenching on gonadotropin serum levels in mice. Short-term
thymulin quenching was performed as described in Fig. 3. Control mice received anti-KLH
rabbit serum, whereas experimental mice received rabbit anti-FTS serum. All mice were killed
at 45 days of age. Other details are as described in Fig. 2. **P < 0.01, significance of differences
between control and experimental mice.
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Impact of short-term serum thymulin quenching on gonadotropic cell morphology in C57BL/
6 mice. Mice were submitted to short-term thymulin immunoneutralization as described in Fig.
3 and MATERIALS AND METHODS. Mice were killed at 45 days of age. Pituitary sections
were submitted to immunohistochemistry for LH and FSH (see MATERIALS AND
METHODS). A trend toward hypertrophy and a decrease in numbers in gonadotrophs can be
noticed in the representative experimental (EXP) sections shown compared with the control
(CTR) counterparts. Scale bar, 25 μm.
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Effect of neonatal thymulin gene therapy on serum levels of thymulin in heterozygous (nu/+)
and homozygous (nu/nu) nude mice. Vectors were intramuscularly injected on the day of birth
or the day after (arrow). At postnatal day 13, 3 mice per group were bled and serum thymulin
was assayed. On postnatal days 51 and 52, the remainder of the animals were bled and thymulin
was assayed. Since the volume of serum that can be obtained from newborn mice is exceedingly
small, thymulin could not be reliably determined on postnatal days 1 and 2. Serum thymulin
values (fg/ml) are expressed as means ± SE; n values for data points at days 51 and 52 are
shown above symbols. **P < 0.01, significance of differences between RAd-GFP/TK-injected
animals and RAd-metFTS-injected counterparts.
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Effect of neonatal thymulin gene therapy on serum LH and FSH in nude mice. The indicated
vectors were intramuscularly injected at birth, and the animals were bled 51-52 days afterward
for serum LH and FSH determination. Other details are as described in Fig. 2. *P < 0.05;
**P < 0.01, significance of differences between RAd-GFP/TK-injected animals and
RAdmetFTS-injected counterparts.
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